ELSEVIER

Diabetes Research and Clinical Practice 44 (1999) 215–217

DIABETES RESEARCH AND CLINICAL PRACTICE

# Author index of volume 44

Adamson, U., see Oskarsson, P. **44**, 165
Andersen, H.U., see O'Brien, T. **44**, 157
Ando, H., see Takamura, T. **44**, 107
Araki, E., see Kaneko, K. **44**, 83

Baqai, S., see Shera, A.S. **44**, 49
Blackett Ngu, K., see Sobngwi, E. **44**, 191

Chanprasertyotin, S., see Puavilai, G. **44**, 21
Chen, C.J., see Chen, K.T. **44**, 59
Chen, K.T., C.J. Chen, E.W. Gregg, D.F. Williamson, K.M.V. Narayan, High prevalence of impaired fasting glucose and type 2 diabetes mellitus in Penghu Islets, Taiwan: evidence of a rapidly emerging epidemic? **44**, 59
Clausen Sjöbom, N., see Oskarsson, P. **44**, 165
Copeland, K.C., see Coss-Bu, J.A. **44**, 175
Coss-Bu, J.A., L.S. Jefferson, S. Stone-McCord, C.-N. Ou, C. Watrin, R. Sachdeva, K.C. Copeland, Evaluation of a real-time blood glucose monitor in children with diabetic ketoacidosis **44**, 175

Deniz, G., see Gul, H. **44**, 93
Doi, Y., see Nakamura, S. **44**, 183

Fujikura, Y., see Ina, K. **44**, 1
Fujishima, M., see Nakamura, S. **44**, 183

Goko, H., A. Matsuoka, W-5 and quin 2-AM reverse the inhibitory effect of insulin on lipolysis due to dibutyryl cAMP **44**, 101
Gregg, E.W., see Chen, K.T. **44**, 59
Gul, H., Z. Odabasi, O. Yildiz, M. Ozata, G. Deniz, O. Vural, A. Isimer, Beneficial effect of thyrotropin-releasing hormone on neuropathy in diabetic rats **44**, 93

Hattori, Y., see Takeda, S. **44**, 199
Hilgertová, J., see Škrha, J. **44**, 27

Ina, K., H. Kitamura, T. Okeda, K. Nagai, Z.Y. Liu, M. Matsuda, Y. Fujikura, Vascular cell adhesion molecule-l expression in the renal interstitium of diabetic KKAy mice **44**, 1
Irie, M., see Takeda, S. **44**, 199
Irvine, S.D., see Mayhan, W.G. **44**, 147
Isimer, A., see Gul, H. **44**, 93
Iwamoto, Y., see Yanagisawa, K. **44**, 41
Iwasaki, N., see Yanagisawa, K. **44**, 41

Jefferson, L.S., see Coss-Bu, J.A. **44**, 175

Kanamori, A., see Tanaka, K. **44**, 137
Kanamori, M., see Yanagisawa, K. **44**, 41
Kaneko, K., T. Shirotani, E. Araki, K. Matsumoto, T. Taguchi, H. Motoshima, K. Yoshizato, H. Kishikawa, M. Shichiri, Insulin inhibits glucagon secretion by the activation of PI3-kinase in In-R1-G9 cells **44**, 83
Karlsen, A.E., see O'Brien, T. **44**, 157
Katafuchi, R., see Nakamura, S. **44**, 183
Khawaja, I.A., see Shera, A.S. **44**, 49
King, H., see Shera, A.S. **44**, 49
Kishikawa, H., see Kaneko, K. **44**, 83
Kitamura, H., see Ina, K. **44**, 1
Kobayashi, K.-i., see Takamura, T. **44**, 107
Kosaka, K., see Yoshinaga, H. **44**, 129
Kvasnička, J., see Škrha, J. **44**, 27

Latha, E., see Ramachandran, A. **44**, 209
Lins, P.-E., see Oskarsson, P. **44**, 165
Liu, Z.Y., see Ina, K. **44**, 1
Lloyd, C.E., T.J. Orchard, Physical and psychological well-being in adults with Type 1 diabetes **44**, 9

Mandrup-Poulsen, T., see O'Brien, T. **44**, 157
Manoharan, M., see Ramachandran, A. **44**, 209
Matsuda, M., see Ina, K. **44**, 1
Matsumoto, K., see Kaneko, K. **44**, 83
Matsuoka, A., see Goko, H. **44**, 101

PII: S0168-8227(99)00072-8

Mayhan, W.G., S.D. Irvine, G.M. Sharpe, Constrictor responses of resistance arterioles during diabetes mellitus **44**, 147
Mbanya, J.-C., see Sobngwi, E. **44**, 191
McDermid, K.P., J. Watterson, S.F. van Eeden, Emphysematous pyelonephritis: case report and review of the literature **44**, 71
Minei, S., see Yanagisawa, K. **44**, 41
Mira, M., see Overland, J. **44**, 123
Moriya, T., see Tanaka, K. **44**, 137
Motoshima, H., see Kaneko, K. **44**, 83
Müller, U.A., see Schiel, R. **44**, 115

Nagai, K., see Ina, K. **44**, 1
Nagai, Y., see Takamura, T. **44**, 107
Nakamura, S., M. Yoshinari, Y. Doi, H. Yoshizumi, R. Katafuchi, Y. Yokomizo, K. Nishiyama, M. Wakisaka, M. Fujishima, Renal complications in patients with diabetes mellitus associated with an A to G mutation of mitochondrial DNA at the 3243 position of leucine tRNA **44**, 183
Narayan, K.M.V., see Chen, K.T. **44**, 59
Nerup, J., see O'Brien, T. **44**, 157
Nishiyama, K., see Nakamura, S. **44**, 183
Nohara, E., see Takamura, T. **44**, 107
Nyolo Moukouri, E., see Sobngwi, E. **44**, 191

O'Brien, T., A.E. Karlsen, H.U. Andersen, T. Mandrup-Poulsen, J. Nerup, Absence of toxicity associated with adenoviral-mediated transfer of the $\beta$-galactosidase reporter gene to neonatal rat islets in vitro **44**, 157
Odabasi, Z., see Gul, H. **44**, 93
Oikawa, S., see Sasaki, A. **44**, 35
Okeda, T., see Ina, K. **44**, 1
Omori, Y., see Yanagisawa, K. **44**, 41
Orchard, T.J., see Lloyd, C.E. **44**, 9
Oskarsson, P., U. Adamson, N. Clausen Sjöbom, P.-E. Lins, Long-term follow-up of insulin-dependent diabetes mellitus patients with recurrent episodes of severe hypoglycaemia **44**, 165
Ou, C.-N., see Coss-Bu, J.A. **44**, 175
Overland, J., M. Mira, D.K. Yue, Diabetes management: shared care or shared neglect **44**, 123
Ozata, M., see Gul, H. **44**, 93

Puavilai, G., S. Chanprasertyotin, A. Sriphrapradaeng, Diagnostic criteria for diabetes mellitus and other categories of glucose intolerance: 1997 criteria by the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (ADA), 1998 WHO Consultation criteria, and 1985 WHO criteria **44**, 21

Rafique, G., see Shera, A.S. **44**, 49
Ramachandran, A., C. Snehalatha, E. Latha, M. Manoharan, V. Vijay, Impacts of urbanisation on the lifestyle and on the prevalence of diabetes in native Asian Indian population **44**, 209

Sachdeva, R., see Coss-Bu, J.A. **44**, 175
Sanaka, M., see Yanagisawa, K. **44**, 41
Sasaki, A., S. Oikawa, T. Toyota, Microalbuminuria is closely related to diabetic macroangiopathy **44**, 35
Schiel, R., U.A. Müller, Prevalence of sexual disorders in a selection-free diabetic population (JEVIN) **44**, 115
Sharpe, G.M., see Mayhan, W.G. **44**, 147
Shera, A.S., G. Rafique, I.A. Khawaja, S. Baqai, H. King, Pakistan National Diabetes Survey: prevalence of glucose intolerance and associated factors in Baluchistan province **44**, 49
Shichiri, M., see Kaneko, K. **44**, 83
Shirotani, T., see Kaneko, K. **44**, 83
Šindelka, G., see Škrha, J. **44**, 27
Škrha, J., G. Šindelka, J. Kvasnička, J. Hilgertová, Insulin action and fibrinolysis influenced by vitamin E in obese Type 2 diabetes mellitus **44**, 27
Snehalatha, C., see Ramachandran, A. **44**, 209
Sobngwi, E., J.-C. Mbanya, E. Nyolo Moukouri, K. Blackett Ngu, Microalbuminuria and retinopathy in a diabetic population of Cameroon **44**, 191
Sriphrapradaeng, A., see Puavilai, G. **44**, 21
Stone-McCord, S., see Coss-Bu, J.A. **44**, 175

Taguchi, T., see Kaneko, K. **44**, 83
Takamura, T., H. Ando, Y. Nagai, H. Yamashita, E. Nohara, K.-i. Kobayashi, Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulitis and diabetes **44**, 107
Takeda, S., H. Ueshiba, Y. Hattori, M. Irie, Cilnidipine, the N- and L-type calcium channel antagonist, reduced on 24-h urinary catecholamines and C-peptide in hypertensive non-insulin-dependent diabetes mellitus **44**, 199
Tanaka, K., T. Moriya, A. Kanamori, Y. Yajima, Analysis and a long-term follow up of ketosis-onset Japanese NIDDM patients **44**, 137
Toyota, T., see Sasaki, A. **44**, 35

Ueshiba, H., see Takeda, S. **44**, 199

van Eeden, S.F., see McDermid, K.P. **44**, 71
Vijay, V., see Ramachandran, A. **44**, 209
Vural, O., see Gul, H. **44**, 93

Wakisaka, M., see Nakamura, S. **44**, 183
Watrin, C., see Coss-Bu, J.A. **44**, 175
Watterson, J., see McDermid, K.P. **44**, 71
Williamson, D.F., see Chen, K.T. **44**, 59

Yajima, Y., see Tanaka, K. **44**, 137
Yamashita, H., see Takamura, T. **44**, 107
Yanagisawa, K., N. Iwasaki, M. Sanaka, S. Minei, M. Kanamori, Y. Omori, Y. Iwamoto, Polymorphism of the $\beta$3-adrenergic receptor gene and weight gain in pregnant diabetic women **44**, 41
Yildiz, O., see Gul, H. **44**, 93
Yokomizo, Y., see Nakamura, S. **44**, 183

Yoshinaga, H., K. Kosaka, Heterogeneous relationship of early insulin response and fasting insulin level with development of non-insulin-dependent diabetes mellitus in non-diabetic Japanese subjects with or without obesity **44**, 129

Yoshinari, M., see Nakamura, S. **44**, 183
Yoshizato, K., see Kaneko, K. **44**, 83
Yoshizumi, H., see Nakamura, S. **44**, 183
Yue, D.K., see Overland, J. **44**, 123

ELSEVIER

Diabetes Research and Clinical Practice 44 (1999) 219–222

DIABETES RESEARCH AND CLINICAL PRACTICE

# Subject index of volume 44

**Acute-onset NIDDM patients**; Diabetic ketoacidosis; Ketosis; Sugar-containing soft drinks **44**, 137

**Adenovirus**; Islets of Langerhans; Gene therapy; Gene transfer **44**, 157

**β3-Adrenergic receptor gene**; Weight gain; Pregnancy; Body mass index; Non-insulin-dependent diabetes mellitus **44**, 41

**Albuminuria**; Non-insulin-dependent diabetes mellitus; Transferrinuria; Diabetic macroangiopathy **44**, 35

**Arterioles**; Norepinephrine; Thromboxane; Nitric oxide; $N^G$-monomethyl-L-arginine (L-NMMA); Endothelin-1 **44**, 147

**Asian Indians**; Epidemiology of diabetes; Urbanization; Occupation; Determinants of diabetes **44**, 209

**Asians**; Diabetes mellitus; Impaired glucose tolerance; Obesity; Prevalence **44**, 49

**Autoimmune diabetes**; Multiple low-dose streptozotocin; Pioglitazone; PPAR-γ; Thiazolidinedione **44**, 107

**Blood glucose**; Diabetes mellitus; Glucose intolerance; Glucose tolerance test; Impaired fasting glucose; Impaired glucose tolerance **44**, 21

**Body mass index**; β3-Adrenergic receptor gene; Weight gain; Pregnancy; Non-insulin-dependent diabetes mellitus **44**, 41

**Calcium ion**; W-5; Quin 2-AM; Insulin; Dibutyryl cAMP **44**, 101

**Cilnidipine**; NIDDM; Hypertension; Urinary catecholamines; Urinary C-peptide **44**, 199

**Complications**; Shared care; Primary care; Outcomes; Cost-effectiveness **44**, 123

**Cost-effectiveness**; Shared care; Primary care; Outcomes; Complications **44**, 123

**Determinants of diabetes**; Epidemiology of diabetes; Urbanization; Occupation; Asian Indians **44**, 209

**Development of non-insulin-dependent diabetes mellitus**; Early insulin response; Fasting insulin level; Obesity; Japanese **44**, 129

**Diabetes**; Kidney; Pyelonephritis **44**, 71

**Diabetes mellitus**; Glucose intolerance; Blood glucose; Glucose tolerance test; Impaired fasting glucose; Impaired glucose tolerance **44**, 21

**Diabetes mellitus**; IDDM; NIDDM; Sexual disorders; HbA1c; Long-term complications; Quality of life **44**, 115

**Diabetes mellitus**; Impaired glucose tolerance; Obesity; Prevalence; Asians **44**, 49

**Diabetes mellitus**; Nephrotic syndrome; Focal glomerulosclerosis; Mitochondrial DNA mutation; MELAS **44**, 183

**Diabetes**; Quality of life; Hypoglycemia **44**, 9

**Diabetic ketoacidosis**; Acute-onset NIDDM patients; Ketosis; Sugar-containing soft drinks **44**, 137

PII: S0168-8227(99)00073-X

**Diabetic macroangiopathy**; Non-insulin-dependent diabetes mellitus; Albuminuria; Transferrinuria **44**, 35

**Diabetic nephropathy**; Interstitial inflammation; Vascular cell adhesion molecule-l **44**, 1

**Diabetic neuropathy**; Somatosensory evoked potentials; Nerve conduction velocity; Streptozotocin; Rat **44**, 93

**Dibutyryl cAMP**; W-5; Quin 2-AM; Insulin; Calcium ion **44**, 101

**Early insulin response**; Fasting insulin level; Development of non-insulin-dependent diabetes mellitus; Obesity; Japanese **44**, 129

**Endothelin-1**; Norepinephrine; Thromboxane; Nitric oxide; Arterioles; $N^G$-monomethyl-L-arginine (L-NMMA) **44**, 147

**Epidemiology of diabetes**; Urbanization; Occupation; Determinants of diabetes; Asian Indians **44**, 209

**Fasting insulin level**; Early insulin response; Development of non-insulin-dependent diabetes mellitus; Obesity; Japanese **44**, 129

**Fibrinolysis**; Vitamin E; Oxidative stress; Insulin action; Obese Type 2 diabetes mellitus **44**, 27

**Focal glomerulosclerosis**; Diabetes mellitus; Nephrotic syndrome; Mitochondrial DNA mutation; MELAS **44**, 183

**Gene therapy**; Islets of Langerhans; Gene transfer; Adenovirus **44**, 157

**Gene transfer**; Islets of Langerhans; Gene therapy; Adenovirus **44**, 157

**Glucagon secretion**; Pancreatic alpha cells; In-R1-G9 cells; Insulin; PI3-kinase **44**, 83

**Glucose intolerance**; Diabetes mellitus; Blood glucose; Glucose tolerance test; Impaired fasting glucose; Impaired glucose tolerance **44**, 21

**Glucose monitoring**; Ketoacidosis; Pediatrics; Intensive care **44**, 175

**Glucose tolerance test**; Diabetes mellitus; Glucose intolerance; Blood glucose; Impaired fasting glucose; Impaired glucose tolerance **44**, 21

**HbA1c**; Diabetes mellitus; IDDM; NIDDM; Sexual disorders; Long-term complications; Quality of life **44**, 115

**Hypertension**; NIDDM; Cilnidipine; Urinary catecholamines; Urinary C-peptide **44**, 199

**Hypoglycemia**; Diabetes; Quality of life **44**, 9

**IDDM**; Diabetes mellitus; NIDDM; Sexual disorders; HbA1c; Long-term complications; Quality of life **44**, 115

**Impaired fasting glucose**; Diabetes mellitus; Glucose intolerance; Blood glucose; Glucose tolerance test; Impaired glucose tolerance **44**, 21

**Impaired fasting glucose**; Type 2 diabetes; Prevalence; Taiwan **44**, 59

**Impaired glucose tolerance**; Diabetes mellitus; Glucose intolerance; Blood glucose; Glucose tolerance test; Impaired fasting glucose **44**, 21

**Impaired glucose tolerance**; Diabetes mellitus; Obesity; Prevalence; Asians **44**, 49

**In-R1-G9 cells**; Pancreatic alpha cells; Insulin; Glucagon secretion; PI3-kinase **44**, 83

**Insulin action**; Vitamin E; Oxidative stress; Fibrinolysis; Obese Type 2 diabetes mellitus **44**, 27

**Insulin-dependent diabetes mellitus**; Severe hypoglycaemia; Insulin-infusion test; Reproducibility; Risk factors **44**, 165

**Insulin-infusion test**; Insulin-dependent diabetes mellitus; Severe hypoglycaemia; Reproducibility; Risk factors **44**, 165

**Insulin**; Pancreatic alpha cells; In-R1-G9 cells; Glucagon secretion; PI3-kinase **44**, 83

**Insulin**; W-5; Quin 2-AM; Dibutyryl cAMP; Calcium ion **44**, 101

**Intensive care**; Glucose monitoring; Ketoacidosis; Pediatrics **44**, 175

**Interstitial inflammation**; Diabetic nephropathy; Vascular cell adhesion molecule-l **44**, 1

**Islets of Langerhans**; Gene therapy; Gene transfer; Adenovirus **44**, 157

**Japanese**; Early insulin response; Fasting insulin level; Development of non-insulin-dependent diabetes mellitus; Obesity **44**, 129

**Ketoacidosis**; Glucose monitoring; Pediatrics; Intensive care **44**, 175

**Ketosis**; Acute-onset NIDDM patients; Diabetic ketoacidosis; Sugar-containing soft drinks **44**, 137

**Kidney**; Diabetes; Pyelonephritis **44**, 71

**Long-term complications**; Diabetes mellitus; IDDM; NIDDM; Sexual disorders; HbA1c; Quality of life **44**, 115

**MELAS**; Diabetes mellitus; Nephrotic syndrome; Focal glomerulosclerosis; Mitochondrial DNA mutation **44**, 183

**Microalbuminuria**; Retinopathy; Nephropathy **44**, 191

**Mitochondrial DNA mutation**; Diabetes mellitus; Nephrotic syndrome; Focal glomerulosclerosis; MELAS **44**, 183

**Multiple low-dose streptozotocin**; Autoimmune diabetes; Pioglitazone; PPAR-$\gamma$; Thiazolidinedione **44**, 107

**Nephropathy**; Retinopathy; Microalbuminuria **44**, 191

**Nephrotic syndrome**; Diabetes mellitus; Focal glomerulosclerosis; Mitochondrial DNA mutation; MELAS **44**, 183

**Nerve conduction velocity**; Diabetic neuropathy; Somatosensory evoked potentials; Streptozotocin; Rat **44**, 93

**$N^G$-monomethyl-L-arginine (L-NMMA)**; Norepinephrine; Thromboxane; Nitric oxide; Arterioles; Endothelin-1 **44**, 147

**NIDDM**; Diabetes mellitus; IDDM; Sexual disorders; HbA1c; Long-term complications; Quality of life **44**, 115

**NIDDM**; Hypertension; Cilnidipine; Urinary catecholamines; Urinary C-peptide **44**, 199

**Nitric oxide**; Norepinephrine; Thromboxane; Arterioles; $N^G$-monomethyl-L-arginine (L-NMMA); Endothelin-1 **44**, 147

**Non-insulin-dependent diabetes mellitus**; $\beta$3-Adrenergic receptor gene; Weight gain; Pregnancy; Body mass index **44**, 41

**Non-insulin-dependent diabetes mellitus**; Albuminuria; Transferrinuria; Diabetic macroangiopathy **44**, 35

**Norepinephrine**; Thromboxane; Nitric oxide; Arterioles; $N^G$-monomethyl-L-arginine (L-NMMA); Endothelin-1 **44**, 147

**Obese Type 2 diabetes mellitus**; Vitamin E; Oxidative stress; Insulin action; Fibrinolysis **44**, 27

**Obesity**; Diabetes mellitus; Impaired glucose tolerance; Prevalence; Asians **44**, 49

**Obesity**; Early insulin response; Fasting insulin level; Development of non-insulin-dependent diabetes mellitus; Japanese **44**, 129

**Occupation**; Epidemiology of diabetes; Urbanization; Determinants of diabetes; Asian Indians **44**, 209

**Outcomes**; Shared care; Primary care; Cost-effectiveness; Complications **44**, 123

**Oxidative stress**; Vitamin E; Insulin action; Fibrinolysis; Obese Type 2 diabetes mellitus **44**, 27

**Pancreatic alpha cells**; In-R1-G9 cells; Insulin; Glucagon secretion; PI3-kinase **44**, 83

**Pediatrics**; Glucose monitoring; Ketoacidosis; Intensive care **44**, 175

**PI3-kinase**; Pancreatic alpha cells; In-R1-G9 cells; Insulin; Glucagon secretion **44**, 83

**Pioglitazone**; Autoimmune diabetes; Multiple low-dose streptozotocin; PPAR-$\gamma$; Thiazolidinedione **44**, 107

**PPAR-$\gamma$**; Autoimmune diabetes; Multiple low-dose streptozotocin; Pioglitazone; Thiazolidinedione **44**, 107

**Pregnancy**; $\beta$3-Adrenergic receptor gene; Weight gain; Body mass index; Non-insulin-dependent diabetes mellitus **44**, 41

**Prevalence**; Diabetes mellitus; Impaired glucose tolerance; Obesity; Asians **44**, 49

**Prevalence**; Type 2 diabetes; Impaired fasting glucose; Taiwan **44**, 59

**Primary care**; Shared care; Outcomes; Cost-effectiveness; Complications **44**, 123

**Pyelonephritis**; Kidney; Diabetes **44**, 71

**Quality of life**; Diabetes; Hypoglycemia **44**, 9

**Quality of life**; Diabetes mellitus; IDDM; NIDDM; Sexual disorders; HbA1c; Long-term complications **44**, 115

**Quin 2-AM**; W-5; Insulin; Dibutyryl cAMP; Calcium ion **44**, 101

**Rat**; Diabetic neuropathy; Somatosensory evoked potentials; Nerve conduction velocity; Streptozotocin **44**, 93

**Reproducibility**; Insulin-dependent diabetes mellitus; Severe hypoglycaemia; Insulin-infusion test; Risk factors **44**, 165

**Retinopathy**; Nephropathy; Microalbuminuria **44**, 191

**Risk factors**; Insulin-dependent diabetes mellitus; Severe hypoglycaemia; Insulin-infusion test; Reproducibility **44**, 165

**Severe hypoglycaemia**; Insulin-dependent diabetes mellitus; Insulin-infusion test; Reproducibility; Risk factors **44**, 165

**Sexual disorders**; Diabetes mellitus; IDDM; NIDDM; HbA1c; Long-term complications; Quality of life **44**, 115

**Shared care**; Primary care; Outcomes; Cost-effectiveness; Complications **44**, 123

**Somatosensory evoked potentials**; Diabetic neuropathy; Nerve conduction velocity; Streptozotocin; Rat **44**, 93

**Streptozotocin**; Diabetic neuropathy; Somatosensory evoked potentials; Nerve conduction velocity; Rat **44**, 93

**Sugar-containing soft drinks**; Acute-onset NIDDM patients; Diabetic ketoacidosis; Ketosis **44**, 137

**Taiwan**; Type 2 diabetes; Impaired fasting glucose; Prevalence **44**, 59

**Thiazolidinedione**; Autoimmune diabetes; Multiple low-dose streptozotocin; Pioglitazone; PPAR-$\gamma$ **44**, 107

**Thromboxane**; Norepinephrine; Nitric oxide; Arterioles; $N^G$-monomethyl-L-arginine (L-NMMA); Endothelin-1 **44**, 147

**Transferrinuria**; Non-insulin-dependent diabetes mellitus; Albuminuria; Diabetic macroangiopathy **44**, 35

**Type 2 diabetes**; Impaired fasting glucose; Prevalence; Taiwan **44**, 59

**Urbanization**; Epidemiology of diabetes; Occupation; Determinants of diabetes; Asian Indians **44**, 209

**Urinary catecholamines**; NIDDM; Hypertension; Cilnidipine; Urinary C-peptide **44**, 199

**Urinary C-peptide**; NIDDM; Hypertension; Cilnidipine; Urinary catecholamines **44**, 199

**Vascular cell adhesion molecule-l**; Diabetic nephropathy; Interstitial inflammation **44**, 1

**Vitamin E**; Oxidative stress; Insulin action; Fibrinolysis; Obese Type 2 diabetes mellitus **44**, 27

**Weight gain**; $\beta$3-Adrenergic receptor gene; Pregnancy; Body mass index; Non-insulin-dependent diabetes mellitus **44**, 41

**W-5**; Quin 2-AM; Insulin; Dibutyryl cAMP; Calcium ion **44**, 101